$BIO-B

BIO RAD LABORATORIES INC

CIK:0000012208|SEC Filings

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Net sales	$ 651,000	$ 651,600	$ 1,243,100	$ 1,237,000
Cost of goods sold	305,200	306,300	587,900	585,700
Gross profit	345,800	345,300	655,200	651,300
Selling, general and administrative expense	212,000	207,700	424,400	416,500
Research and Development Expense	61,200	60,500	124,100	134,000
Segment profit (loss)	72,600	77,100	106,700	100,800
Interest expense	12,100	12,600	24,400	24,600
Foreign exchange (gains) losses, net	(200)	1,100	(2,600)	(1,600)
Marketable Securities, Unrealized (Gain) Loss	(458,000)	(334,400)	280,200	(366,200)
Other Nonoperating Income (Expense)	23,400	16,200	47,600	53,400
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	542,100	414,000	(147,700)	497,400
(Provision) benefit for income taxes	(170,700)	(96,200)	(8,000)	(115,600)
Net income attributable to Bio-Rad	$ 371,400	$ 317,800	$ (155,700)	$ 381,800
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 13.89	$ 11.67	$ (5.80)	$ 13.84
Weighted average common shares - basic	26,746	27,226	26,852	27,581
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 13.85	$ 11.67	$ (5.80)	$ 13.84
Weighted average common shares - diluted	26,814	27,228	26,852	27,589

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Cash received from customers	$ 1,242,700	$ 1,304,900
Cash paid to suppliers and employees	(1,054,600)	(993,900)
Interest paid, net	(23,300)	(23,100)
Income tax payments, net	(24,300)	(56,100)
Investment proceeds and miscellaneous receipts, net	49,000	48,900
Proceeds from forward foreign exchange contracts, net	17,300	(34,300)
Net cash provided by operating activities	206,800	246,400
Cash flows from investing activities:
Capital expenditures	(62,000)	(80,100)
Proceeds from dispositions of property, plant and equipment	0	100
(Payments for) proceeds from acquisitions, net of cash received	1,100	(216,700)
Payments for purchases of marketable securities and investments	(410,300)	(306,600)
Proceeds from Sale of Debt Securities, Available-for-sale	271,900	445,600
Proceeds from maturities of marketable securities and investments	39,400	45,200
Net cash used in investing activities	(159,900)	(112,500)
Cash flows from financing activities:
Payments on long-term borrowings	(300)	(300)
Proceeds from Issuance of Common Stock	7,600	8,500
Tax payments from net share settlement	(100)	(100)
Payments for purchases of treasury stock	(79,300)	(242,100)
Option Premium Proceeds For Structured Purchases Of Treasury Stock	500	0
Net cash used in financing activities	(71,600)	(234,000)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	11,300	(18,000)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(13,400)	(118,100)
Beginning Cash, Cash Equivalents, and Restricted Cash	532,200	489,800
Cash and cash equivalents	517,000	369,300
Restricted Cash, Current	1,600	2,000
Restricted Cash, Noncurrent	200	400
Ending Cash, Cash Equivalents, and Restricted Cash	$ 518,800	$ 371,700

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
ASSETS:
Cash and cash equivalents	$ 517,000	$ 529,800
Short-term investments	1,101,500	1,010,900
Accounts receivable, net	441,800	460,600
Inventory	780,600	740,700
Prepaid expenses	147,800	136,500
Other current assets	31,800	27,700
Total current assets	3,020,500	2,906,200
Property, plant and equipment, net	517,900	539,900
Operating lease right-of-use assets	154,000	170,000
Goodwill, net	574,300	579,800
Purchased intangibles, net	160,000	174,300
Other investments	5,723,600	6,103,600
Other assets	101,700	102,700
Assets	10,252,000	10,576,500
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable	143,500	129,000
Accrued payroll and employee benefits	150,500	172,300
Current maturities of long-term debt and notes payable	400,700	1,300
Income and other taxes payable	74,200	36,600
Current operating lease liabilities	33,600	36,100
Other current liabilities	158,800	141,700
Total current liabilities	961,300	517,000
Long-term debt, net of current maturities	803,000	1,201,700
Deferred income taxes	982,200	1,059,400
Operating lease liabilities	133,100	145,700
Other long-term liabilities	198,500	199,100
Total liabilities	3,078,100	3,122,900
Stockholders' equity:
Preferred Stock, Value, Issued	0	0
Additional paid-in capital	502,900	476,000
Retained earnings	8,020,600	8,176,300
Accumulated other comprehensive loss	(271,300)	(189,100)
Total stockholders' equity	7,173,900	7,453,600
Total liabilities and stockholders' equity	10,252,000	10,576,500
Common Class A [Member]
Stockholders' equity:
Common stock	0	0
Common Class B [Member]
Stockholders' equity:
Common stock	0	0
Treasury Stock, Common
Stockholders' equity:
Treasury stock	$ (1,078,300)	$ (1,009,600)